TRIA™ Polymer Surgical Valves Surpass 200 Patient Life Years
Foldax® , Inc., a leader in the development of innovative, polymer heart valves, today announced that its TRIA valves have surpassed 200 patient life years in human recipients.
- Foldax® , Inc., a leader in the development of innovative, polymer heart valves, today announced that its TRIA valves have surpassed 200 patient life years in human recipients.
- TRIA valves are intended to improve the lifetime management of heart valve disease in patients.
- The novel polymer material enables TRIA valves to be robotically produced, minimizing manpower and process, and maximizing product quality and precision.
- The TRIA valves have demonstrated excellent and stable hemodynamics clinically and have restored patient quality of life without requiring long-term use of anticoagulants.